News

Filter

Current filters:

USAOphthalmicsNovartis

FDA approves Alcon's Pazeo for ocular allergy itch relief

FDA approves Alcon's Pazeo for ocular allergy itch relief

02-02-2015

The US Food and Drug Administration has approved Pazeo (olopatadine hydrochloride ophthalmic solution)…

AlconHealthHealth Medical PharmaNovartisOlopatadine hydrochlorideOphthalmicsPharmaceuticalUSA

Akorn files ANDA for generic Durezol

16-01-2015

US generic drugmaker Akorn has confirmed that it has filed an Abbreviated New Drug Application (ANDA)…

AkornAlconDurezolGenericsNovartisOphthalmicsPatentsRegulationUSA

Novartis' Alcon granted additional pediatric indication by the European Commission for Travatan

Novartis' Alcon granted additional pediatric indication by the European Commission for Travatan

23-12-2014

Eyecare specialist Alcon, the second-largest division of Swiss drug major Novartis, has been granted…

AlconNovartisOphthalmicsPharmaceuticalRegulationTravatanUSA

Avastin could save the USA $29 billion if used instead of Lucentis

Avastin could save the USA $29 billion if used instead of Lucentis

04-06-2014

Using Avastin (bevacizumab) from Swiss drug major Roche instead of Lucentis (ranibizumab) from fellow…

AvastinBevacizumabFinancialLucentisNovartisOphthalmicsPharmaceuticalRocheUSA

US and European retinal specialists view AMD treatments

US and European retinal specialists view AMD treatments

14-03-2014

Surveyed US and European retinal specialists ascribe a moderate to high unmet need for wet age-related…

BayerEuropeEyleaFovistaLucentisMarkets & MarketingNovartisOphthalmicsOphthotechPharmaceuticalRegeneronRocheUSA

COMPANY SPOTLIGHT

Menarini

Back to top